Connecticut’s Medical Marijuana Program Board of Physicians has unanimously approved the addition of female orgasmic disorder (FOD) as a qualifying condition for medical cannabis treatment. This marks a significant step forward in addressing a condition that affects up to 41 percent of women, who experience delayed, infrequent, or absent orgasms.
The decision was influenced by a petition from Suzanne Mulvehill, a clinical sexologist and executive director of the Female Orgasm Research Institute. Mulvehill’s research indicates that over 70 percent of patients with FOD reported increased orgasm ease and frequency with cannabis use, and about 67 percent experienced improved sexual satisfaction.
Despite these promising findings, Mulvehill emphasized that discussing women’s sexual satisfaction remains stigmatized. She compared the situation to erectile dysfunction treatments available for men, arguing that medical cannabis could provide a similar solution for women.
While the board’s approval is a critical step, the recommendation now goes to the commissioner of the Department of Consumer Protection for final determination. If approved, Connecticut will join Illinois in recognizing FOD as a qualifying condition for medical cannabis.
Medical Cannabis for Autism Spectrum Disorder Gains Approval in Connecticut
In a notable expansion of Connecticut’s medical cannabis program, the state’s Medical Marijuana Program Board of Physicians has approved autism spectrum disorder (ASD) as a qualifying condition. This decision aligns with increasing recognition of cannabis’s potential benefits for managing symptoms associated with ASD.
The board’s decision reflects a growing body of research and patient advocacy highlighting the therapeutic benefits of cannabis for individuals with ASD. While the approval marks a significant milestone, the final decision rests with the commissioner of the Department of Consumer Protection.
If enacted, this policy change could provide a new avenue of relief for many individuals and families managing ASD in Connecticut, complementing existing treatments and improving quality of life.
Vice President Harris Advocates for Federal Marijuana Legalization
In a recent meeting with activists, Vice President Kamala Harris reiterated the administration’s commitment to legalizing marijuana at the federal level. Harris emphasized the need for a unified approach to cannabis regulation, highlighting the potential benefits for both medical and recreational use.
This renewed push for federal legalization comes as several states, including Connecticut, continue to expand their medical cannabis programs. The inclusion of conditions like female orgasmic disorder and autism spectrum disorder in state programs underscores the growing recognition of cannabis’s therapeutic potential.
As the federal debate continues, state-level advancements offer a glimpse into the future of cannabis policy and its impact on public health and wellness.
The Science Behind Cannabis and Female Orgasmic Disorder
Recent developments in Connecticut have brought attention to the potential benefits of cannabis for treating female orgasmic disorder (FOD). Suzanne Mulvehill, a clinical sexologist, has been at the forefront of this movement, presenting research that shows significant improvements in orgasm ease and frequency among women with FOD who use cannabis.
The underlying mechanisms of cannabis’s effects on sexual function are still being studied. One theory, proposed by Mulvehill and Dr. Jordan Tishler, suggests that cannabis interacts with the brain’s default mode network, which moderates cognitive distraction—a known cause of FOD. Another theory, neuroplasticity, proposes that cannabis facilitates brain cell growth and neural development, which may help some women learn to orgasm.
While more research is needed to fully understand these mechanisms, the approval of FOD as a qualifying condition for medical cannabis in Connecticut represents a promising step forward in addressing this often-overlooked condition.
